Home › Research › Mild cognitive impairment
Polypharmacy and risk of dementia progression in older adults with mild cognitive impairment: A longitudinal cohort study
Ying‐Hsin Hsu, Chih‐Kuang Liang, Ming-Yueh Chou, Hsiu‐Chu Shen, Yu‐Chun Wang, Hirotaka Iwaki, Yu‐Te Lin, Yang Cheng Fann. Alzheimer s & Dementia Translational Research & Clinical Interventions, 2025-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
= 0.005). Cox regression analysis revealed that polypharmacy was significantly associated with a reduced risk of MCI progression to dementia (hazard ratio [HR] = 0.49, 95% confidence interval [CI]: 0.31 to 0.78) after adjusting for covariates. Medication counts ranging from ≥5 to ≥8 were significantly associated with a reduced dementia risk, without a clear cut-off. Further analysis suggested that antihypertensive and lipid-modifying drugs were associated with a reduced risk of dementia progression. Our findings suggest that polypharmacy is associated with a lower risk of progression to dementia in people with MCI, highlighting the importance of medication appropriateness over medication count. Future research should optimize pharmacological strategies to balance the risks and benefits of polypharmacy in older adults with MCI. Highlights: Polypharmacy was linked to reduced dementia risk in older adults with MCI.No clear medication threshold (≥5 to ≥8) for dementia risk reduction was found.Specific medications were associated with a lower risk of dementia progression.The importance of medication purpose and type over medication count is highlighted.Future studies should optimize pharmacological strategies in older adults with MCI.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. Polypharmacy was associated with a reduced risk of progression from mild cognitive impairment to dementia, and antihypertensive and lipid-modifying drugs were also linked to reduced risk. The authors note the importance of medication appropriateness over medication count, and this is an observational association that does not establish that any medication prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hsu, Y., Liang, C., Chou, M.-Y., Shen, H., Wang, Y., Iwaki, H., et al. (2025). Polypharmacy and risk of dementia progression in older adults with mild cognitive impairment: A longitudinal cohort study. Alzheimer s & Dementia Translational Research & Clinical Interventions. https://doi.org/10.1002/trc2.70179
Vancouver
Hsu Y, Liang C, Chou M.-Y, Shen H, Wang Y, Iwaki H, et al. Polypharmacy and risk of dementia progression in older adults with mild cognitive impairment: A longitudinal cohort study. Alzheimer s & Dementia Translational Research & Clinical Interventions. 2025. doi:10.1002/trc2.70179. PMID: 41268047.
BibTeX
@article{hsu2025-41268047,
author = {Hsu, Ying‐Hsin and Liang, Chih‐Kuang and Chou, Ming-Yueh and Shen, Hsiu‐Chu and Wang, Yu‐Chun and Iwaki, Hirotaka and Lin, Yu‐Te and Fann, Yang Cheng},
title = {{Polypharmacy and risk of dementia progression in older adults with mild cognitive impairment: A longitudinal cohort study}},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2025},
doi = {10.1002/trc2.70179},
pmid = {41268047},
url = {https://doi.org/10.1002/trc2.70179}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Cox regression analysis revealed that polypharmacy was significantly associated with a reduced risk of MCI progression to dementia (hazard ratio [HR] = 0.49, 95% confidence interval [CI]: 0.31 to 0.78) after adjusting for covariates.
- Medication counts ranging from ≥5 to ≥8 were significantly associated with a reduced dementia risk, without a clear cut-off.
- Further analysis suggested that antihypertensive and lipid-modifying drugs were associated with a reduced risk of dementia progression.
- Our findings suggest that polypharmacy is associated with a lower risk of progression to dementia in people with MCI, highlighting the importance of medication appropriateness over medication count.
- Future research should optimize pharmacological strategies to balance the risks and benefits of polypharmacy in older adults with MCI.
Why it matters
Polypharmacy was associated with a reduced risk of progression from mild cognitive impairment to dementia, and antihypertensive and lipid-modifying drugs were also linked to reduced risk. The authors note the importance of medication appropriateness over medication count, and this is an observational association that does not establish that any medication prevents dementia.
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 48/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia Translational Research & Clinical Interventions) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yang Cheng Fann: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41268047) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/trc2.70179
- PubMed: 41268047
- Original source →
- Free full text: Alzheimer s & Dementia Translational Research & Clinical Interventions →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.